^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Sci
    Title:

    Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer

    Published date:
    09/15/2023
    Excerpt:
    In conclusion, gilteritinib demonstrated significantly improved antitumor efficacy compared with alectinib against ALK-rearranged NSCLC cells…
    DOI:
    https://doi.org/10.1111/cas.15958